Catherine A Koss1, Paul Natureeba, Dalsone Kwarisiima, Mike Ogena, Tamara D Clark, Peter Olwoch, Deborah Cohan, Jaffer Okiring, Edwin D Charlebois, Moses R Kamya, Diane V Havlir. 1. *Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA; †Makerere University-University of California, San Francisco Research Collaboration, Kampala, Uganda; ‡Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, CA; §Center for AIDS Prevention Studies, Department of Medicine, University of California, San Francisco, San Francisco, CA; and ‖Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Abstract
BACKGROUND:Lifelong antiretroviral therapy (ART) is recommended for all HIV-infected pregnant women, but early studies suggest that women often drop out of care postpartum and data are limited on virologic outcomes. METHODS: We evaluated viral suppression (primary outcome) and retention in care up to 5 years after ART initiation among HIV-infected women who started lifelong ART during pregnancy, irrespective of CD4 count, in a study in rural Uganda (NCT00993031). Participants were followed in the study for up to 1 year postpartum, then referred to clinics in surrounding communities. A random sample (N = 200) was invited to participate in a cross-sectional follow-up study after completing the trial, involving one visit for a questionnaire and pregnancy and HIV-1 RNA testing. Retention in care was defined as having attended an HIV clinic in the last 90 days. Logistic regression models were used to examine factors associated with viral suppression (HIV-1 RNA <400 copies/ml) at follow-up. RESULTS: One hundred fifty women (75%) were successfully contacted for follow-up at a median of 4.2 years after starting ART; 135 were retained in care [90%, 95% confidence interval (CI): 84.0% to 94.3%] and 121 demonstrated viral suppression (80.7%, 95% CI: 73.4% to 86.7%). Women who had disclosed their HIV status to their primary partner had greater odds of viral suppression (adjusted odds ratio: 4.51, 95% CI: 1.02 to 19.8). CONCLUSIONS: High rates of viral suppression can be achieved up to 5 years after initiating ART during pregnancy among women retained in care. Interventions to facilitate disclosure may improve long-term outcomes among women who initiate ART during pregnancy under universal treatment.
RCT Entities:
BACKGROUND: Lifelong antiretroviral therapy (ART) is recommended for all HIV-infected pregnant women, but early studies suggest that women often drop out of care postpartum and data are limited on virologic outcomes. METHODS: We evaluated viral suppression (primary outcome) and retention in care up to 5 years after ART initiation among HIV-infectedwomen who started lifelong ART during pregnancy, irrespective of CD4 count, in a study in rural Uganda (NCT00993031). Participants were followed in the study for up to 1 year postpartum, then referred to clinics in surrounding communities. A random sample (N = 200) was invited to participate in a cross-sectional follow-up study after completing the trial, involving one visit for a questionnaire and pregnancy and HIV-1 RNA testing. Retention in care was defined as having attended an HIV clinic in the last 90 days. Logistic regression models were used to examine factors associated with viral suppression (HIV-1 RNA <400 copies/ml) at follow-up. RESULTS: One hundred fifty women (75%) were successfully contacted for follow-up at a median of 4.2 years after starting ART; 135 were retained in care [90%, 95% confidence interval (CI): 84.0% to 94.3%] and 121 demonstrated viral suppression (80.7%, 95% CI: 73.4% to 86.7%). Women who had disclosed their HIV status to their primary partner had greater odds of viral suppression (adjusted odds ratio: 4.51, 95% CI: 1.02 to 19.8). CONCLUSIONS: High rates of viral suppression can be achieved up to 5 years after initiating ART during pregnancy among women retained in care. Interventions to facilitate disclosure may improve long-term outcomes among women who initiate ART during pregnancy under universal treatment.
Authors: Elvin H Geng; David V Glidden; Nneka Emenyonu; Nicolas Musinguzi; Mwebwesa Bosco Bwana; Torsten B Neilands; Winnie Muyindike; Constantin T Yiannoutsos; Steven G Deeks; David R Bangsberg; Jeffrey N Martin Journal: Trop Med Int Health Date: 2010-06 Impact factor: 2.622
Authors: Sheri D Weiser; Edward A Frongillo; Kathleen Ragland; Robert S Hogg; Elise D Riley; David R Bangsberg Journal: J Gen Intern Med Date: 2008-10-25 Impact factor: 5.128
Authors: Lynn T Matthews; Heather B Ribaudo; Angela Kaida; Kara Bennett; Nicholas Musinguzi; Mark J Siedner; Jerome Kabakyenga; Peter W Hunt; Jeffrey N Martin; Yap Boum; Jessica E Haberer; David R Bangsberg Journal: J Acquir Immune Defic Syndr Date: 2016-04-01 Impact factor: 3.731
Authors: Sandro Mancinelli; Clementina Maria Galluzzo; Mauro Andreotti; Giuseppe Liotta; Haswel Jere; Jean-Baptiste Sagno; Roberta Amici; Maria Franca Pirillo; Paola Scarcella; Maria Cristina Marazzi; Stefano Vella; Leonardo Palombi; Marina Giuliano Journal: AIDS Res Hum Retroviruses Date: 2016-05-05 Impact factor: 2.205
Authors: Adam R Aluisio; Rose Bosire; Betz Bourke; Ann Gatuguta; James N Kiarie; Ruth Nduati; Grace John-Stewart; Carey Farquhar Journal: J Acquir Immune Defic Syndr Date: 2016-10-01 Impact factor: 3.731
Authors: Andreas D Haas; Lyson Tenthani; Malango T Msukwa; Kali Tal; Andreas Jahn; Oliver J Gadabu; Adrian Spoerri; Frank Chimbwandira; Joep J van Oosterhout; Olivia Keiser Journal: Lancet HIV Date: 2016-03-09 Impact factor: 12.767
Authors: Catherine A Koss; Paul Natureeba; Albert Plenty; Flavia Luwedde; Julia Mwesigwa; Veronica Ades; Edwin D Charlebois; Tamara D Clark; Jane Achan; Theodore Ruel; Bridget Nzarubara; Moses R Kamya; Diane V Havlir; Deborah Cohan Journal: J Acquir Immune Defic Syndr Date: 2014-10-01 Impact factor: 3.731
Authors: Catherine A Koss; Paul Natureeba; Dorcas Nyafwono; Albert Plenty; Julia Mwesigwa; Bridget Nzarubara; Tamara D Clark; Theodore D Ruel; Jane Achan; Edwin D Charlebois; Deborah Cohan; Moses R Kamya; Diane V Havlir; Sera L Young Journal: J Acquir Immune Defic Syndr Date: 2016-03-01 Impact factor: 3.731
Authors: Brandon A Knettel; Cody Cichowitz; James Samwel Ngocho; Elizabeth T Knippler; Lilian N Chumba; Blandina T Mmbaga; Melissa H Watt Journal: J Acquir Immune Defic Syndr Date: 2018-04-15 Impact factor: 3.731
Authors: Jean B Nachega; Nadia A Sam-Agudu; Lynne M Mofenson; Mauro Schechter; John W Mellors Journal: Clin Infect Dis Date: 2018-05-02 Impact factor: 9.079
Authors: Stephen Opoku; Samuel Asamoah Sakyi; Nana Kwame Ayisi-Boateng; Anthony Kwame Enimil; Ebenezer Senu; Richard Owusu Ansah; Bismark Dankwah Aning; Diana Atsieno Ojuang; Doreen Nafula Wekesa; Fatima Osman Ahmed; Chidinma B Okeke; Ama Darkoaa Sarfo Journal: AIDS Res Ther Date: 2022-05-25 Impact factor: 2.846
Authors: Aaloke Mody; Izukanji Sikazwe; Nancy L Czaicki; Mwanza Wa Mwanza; Theodora Savory; Kombatende Sikombe; Laura K Beres; Paul Somwe; Monika Roy; Jake M Pry; Nancy Padian; Carolyn Bolton-Moore; Charles B Holmes; Elvin H Geng Journal: PLoS Med Date: 2018-06-05 Impact factor: 11.069
Authors: Maganizo B Chagomerana; William C Miller; Jennifer H Tang; Irving F Hoffman; Bryna J Harrington; Bethany DiPrete; Shaphil Wallie; Allan Jumbe; Laura Limarzi; Mina C Hosseinipour Journal: PLoS One Date: 2018-12-13 Impact factor: 3.240
Authors: Lisa L Abuogi; John M Humphrey; Christian Mpody; Marcel Yotebieng; Pamela M Murnane; Kate Clouse; Lindah Otieno; Craig R Cohen; Kara Wools-Kaloustian Journal: J Virus Erad Date: 2018-11-15
Authors: Nathan Ford; Martina Penazzato; Marco Vitoria; Meg Doherty; Mary-Ann Davies; Elizabeth Zaniewski; Olga Tymejczyk; Matthias Egger; Denis Nash Journal: J Virus Erad Date: 2018-11-15